Company Description
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo.
The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
| Country | United States |
| Founded | 1997 |
| IPO Date | Oct 29, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 85 |
| CEO | Hermann Luebbert |
Contact Details
Address: 120 Presidential Way, Suite 330 Woburn, Massachusetts 01801 United States | |
| Phone | 781 245 1325 |
| Website | biofrontera-us.com |
Stock Details
| Ticker Symbol | BFRI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001858685 |
| CUSIP Number | 09077D100 |
| ISIN Number | US09077D2099 |
| Employer ID | 47-3765675 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Hermann Luebbert | Chief Executive Officer |
| Eugene Leffler | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | SCHEDULE 13D/A | Filing |
| Dec 5, 2024 | D | Notice of Exempt Offering of Securities |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |